FB Pixel no scriptKrASIA | Decoding China's tech and business pulse
MENU
KrASIA

News

With USD 80 million in funding, Syfe sets sights on APAC’s “mass affluent”

2 mins read

Pulses

China tests dual-target weight drug

just now
Sixth Tone
China is preparing to approve mazdutide, its first domestically developed dual-target obesity drug, after Phase 3 trials showed nearly half of higher-dose patients lost at least 15% body weight. Created by Innovent Biologics, the drug activates both GLP-1 and GCGR receptors, enhancing metabolism and reducing liver fat. A launch is expected later this year.
See All

Icon for Editor’s PicksEditor’s Picks

Insights

Indonesia seeks to stitch competing interests to boost textile sector

The prospect of US tariffs has added to the industry’s deep-rooted challenges.

6 mins read
  • Insights

    Beneath the bureaucracy: How state capital made (and remade) China’s venture ecosystem

    30 mins read

Venture RoundupVenture Roundup